Based on the genomic action of the receptors, which requires specific compartmentalization, it is reasonable to hypothesize that nuclear activation of PPARγ acting as tumor suppressor exerts a potential protective role against breast cancer development, whereas the presence of inactive cytoplasmic PPARγ could be a marker of poor prognosis in breast cancer patients. This evidence concerns the gene PPARG and breast carcinoma.